BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

At the head of the biosimilar pack, Amgen’s challenger to Humira launches in the US
With at least six others behind it, Amgen Inc.’s Amjevita is leading a 2023 U.S. biosimilars charge to challenge the all-time biggest-selling drug, Humira (adalimumab),...

More in BioWorld

BioWorld MedTech

Aktiia to bring continuous blood pressure monitor to US
Aktiia SA’s wrist-worn, continuous blood pressure monitor, which has been in use in the EU since 2021, could soon be coming to the U.S. The Aktiia bracelet uses...

More in BioWorld MedTech

BioWorld Science

T-cell study reveals autoimmune component of atherosclerosis
The combination of two sequencing techniques has unveiled features of a subpopulation of cells that could be producing plaques in atherosclerosis. This process is...

More in BioWorld Science

BioWorld Asia

CS Pharma gains Chinese rights to Daewoong’s antifibrotic agent, bersiporocin, in $336M deal
Daewoong Pharmaceutical Ltd. has out-licensed greater China rights for its idiopathic pulmonary fibrosis (IPF) candidate, bersiporocin (DWN-2088), to CS Pharmaceuticals...

More in BioWorld Asia

BioWorld Insider Podcast

BioWorld Science Managing Editor Anette Breindl discusses her new analysis of multiple studies related to weight loss, metabolic health and fitness which in many ways goes against the mainstream health care state of mind about obesity.